Goldman Sachs analysts added Alnylam (ALNY) to the firm’s US Conviction List as part of its monthly update. The company is at an inflection point as its key asset, Amvuttra’s, will likely launch in ATTR-cardiomyopathy, which will drive the next leg of growth, the firm contends. It has a Buy rating on Alnylam with a $371 price target
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio